Investigational drug · Phase 3
MRI contrast-enhancing preparations
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Sclerosis.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "MRI contrast-enhancing preparations"
First trial start
2021
Jun 7, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MRI contrast-enhancing preparations", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Sclerosis
Approved drugs for the same conditions: Multiple sclerosis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "MRI contrast-enhancing preparations" as an intervention, largest first.
- Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07325292 · 160 participants (planned) · Start Jan 14, 2026 · Primary completion Jul 15, 2027
Drug: Frexalimab; Frexalimab and 1 more · For: Multiple Sclerosis
Sites: Cullman, Alabama; Homewood, Alabama; Phoenix, Arizona · 68 sites in all
- Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple SclerosisPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT04879628 · 129 participants · Start Jun 7, 2021 · Primary completion Sep 21, 2022
Drug: SAR441344 IV; placebo IV and 3 more · For: Multiple Sclerosis
Sites: Phoenix, Arizona; Tampa, Florida; Charlotte, North Carolina · 37 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Multiple Sclerosis
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- FenebrutinibRO7010939, GDC-0853Phase 36 trials
Roche (Genentech) · Relapsing Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
- IMU-838Vidofludimus calciumPhase 33 trials
Immunic AG · Relapsing-Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
- MRI contrast-enhancing agentsPhase 33 trials
Sanofi · Multiple Sclerosis
- KYV-101Phase 32 trials
Kyverna Therapeutics · Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
- zamtocabtagene autoleucelMB-CART2019.1Phase 25 trials
Miltenyi Biomedicine GmbH · CAR T Cell Therapy, Mantle Cell Lymphoma (MCL), Multiple Sclerosis
- Allogeneic umbilical cord mesenchymal stem cellsPhase 23 trials
Ever Supreme Bio Technology Co., Ltd. · COVID-19 Infection, Multiple Sclerosis, ST Elevation Myocardial Infarction
- Autologous HB-adMSCsPhase 22 trials
Hope Biosciences LLC · Traumatic Brain Injury, Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.